(NASDAQ: EYPT) Eyepoint's forecast annual revenue growth rate of 350.17% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.43%.
Eyepoint's revenue in 2026 is $2,789,000.On average, 15 Wall Street analysts forecast EYPT's revenue for 2026 to be $152,164,424, with the lowest EYPT revenue forecast at $84,487,895, and the highest EYPT revenue forecast at $244,411,411. On average, 15 Wall Street analysts forecast EYPT's revenue for 2027 to be $1,573,975,003, with the lowest EYPT revenue forecast at $0, and the highest EYPT revenue forecast at $7,965,225,642.
In 2028, EYPT is forecast to generate $26,670,587,012 in revenue, with the lowest revenue forecast at $5,258,164,509 and the highest revenue forecast at $79,732,433,708.